You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

The Role of MRD in Hematologic Malignancies

  • Authors: Aaron C. Logan, MD, PhD
  • CME Released: 9/25/2015
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 9/25/2016, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for hematologists, oncologists, and other clinicians caring for patients with hematologic malignancies.

The goal of this activity is to understand MRD and methods of detection, assess the utility of MRD in the clinical setting, and how it is used in the management of patients with ALL, CLL, NHL, and MM.

Upon completion of this activity, participants will be able to:

  1. Define MRD and review methods of detection
  2. Examine the utility of MRD testing for the assessment of disease status and its effect on treatment decisions
  3. Differentiate the role of MRD in the management of patients with lymphoid malignancies


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author

  • Aaron C. Logan, MD, PhD

    Assistant Professor of Clinical Medicine, Hematology and Blood and Marrow Transplantation, University of California, San Francisco

    Disclosures

    Disclosure: Aaron C. Logan, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Pharmacyclics, Inc.

    Dr Logan does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Logan does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

  • Joanne M. Faysal, MS

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Joanne M. Faysal, MS, has disclosed no relevant financial relationships.

  • Sara Fagerlie, PhD, CHCP

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Sara Fagerlie, PhD, CHCP has disclosed no relevant financial relationships.

CME Reviewer

  • Robert Morris, PharmD

    Associate CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

The Role of MRD in Hematologic Malignancies

Authors: Aaron C. Logan, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 9/25/2015

Valid for credit through: 9/25/2016, 11:59 PM EST

processing....

 

This feature requires the newest version of Flash. You can download it here.
  • Print